


# Q1 2026 Highlights




"I am very pleased with the growth of Iqirvo & Bylvay. With 3 Phase III readouts expected this year and 3 new late-stage programs starting, Ipsen is well-positioned to drive sustainable growth"

**David Loew**  
Chief Executive Officer



## Geography breakdown

Total sales by region: Q1 2026




**North America**  
36.4%  
of total sales

**Europe**  
37.9%  
of total sales

**RoW**  
25.7%  
of total sales

In this map, Europe is defined as the E.U., the U.K., Iceland, Liechtenstein, Norway and Switzerland

## Therapeutic area growth<sup>1</sup>



### Oncology

**Somatuline® autogel®**  
lanreotide

+12.8%

**CABOMETYX®**  
(cabozantinib) tablets

+16.4%

**Decapeptyl®**  
triptorelin

+8.4%

**onivyde®**  
(irinotecan liposome injection)

+12.4%



### Rare Disease

**IQIRVO®**  
ela fibranor

+266.7%

**Bylvay®**  
(odevixibat)

+51.5%



### Neuroscience

**Dysport®**  
ABOBOTULINUM TOXIN A Aesthetics

+24.3%

**Dysport®**  
ABOBOTULINUM TOXIN A Therapeutics

+10.5%

## 2026

### Financial Performance

- Q1 26 sales growth of +22.6% at CER<sup>1</sup>
- Confirmation of 2026 guidance<sup>2</sup>:
  - Total sales growth > 13.0%
  - Core operating margin<sup>3</sup> > 35.0% of total sales

### Pipeline Progression

- Ojemda® (tovorafenib) EU approval in pediatric low-grade glioma
- Three pivotal Phase III readouts expected in H2 2026
- Three late-stage programs starting in 2026